Related content

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

By Miles David   Baselga José   Amadori Dino   Sunpaweravong Patrapim   Semiglazov Vladimir   Knott Adam   Clark Emma   Ross Graham   Swain Sandra  

Breast Cancer Research and Treatment, Vol. 142, Iss. 1, 2013-11 ,pp. : 89-99

Springer Publishing Company

Access to resources Recommend Favorite

Phospho-PRAS40Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer

By  

Oncology Letters, Vol. 9, Iss. 2, 2015-01 ,pp. : 785-789

Spandidos Publications

Access to resources Recommend Favorite

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis

By Zagouri Flora  

Breast Cancer Research and Treatment, Vol. 139, Iss. 1, 2013-05 ,pp. : 13-22

Springer Publishing Company

Access to resources Recommend Favorite

Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe

By Piccart M.J.  

Annals of Oncology, Vol. 12, Iss. 12, 2001-12 ,pp. : 89-94

Springer Publishing Company

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite